RxDoctor Payments Data

Mary Miller, MD

Family Medicine · The Villages, FLNPI 1851331821

Payments from drug & device makers

$1,807in general payments, 2019–2025

Across 99 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$326
  • Astellas Pharma US Inc$263
  • Novo Nordisk$250
  • Exact Sciences$239
  • Merck$164
  • Lilly USA, LLC$111
  • plus $454 from 14 others

What the payments were for

  • Food & beverage$1,70794%
  • Education$1006%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,807 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$196,078
Medicare patients
533
Services billed
1,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$97,179
JardianceEmpagliflozin59$59,559
OzempicSemaglutide37$48,315
EliquisApixaban42$44,137
MounjaroTirzepatide36$41,625
XareltoRivaroxaban22$26,706
MyrbetriqMirabegron22$22,602
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$22,544
Repatha SureclickEvolocumab30$18,060
WegovySemaglutide12$15,552
FarxigaDapagliflozin Propanediol11$11,282
Atorvastatin Calcium355$3,331
Rosuvastatin Calcium219$3,201
Omeprazole232$3,196
Varenicline Tartrate20$3,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$250$63,86749 claims
PfizerEliquis$28$44,13742 claims
Lilly USA, LLCMounjaro$111$41,62536 claims
Astellas Pharma US IncMyrbetriq$263$22,60222 claims
GSKTrelegy Ellipta$71$22,54431 claims
AstraZenecaFarxiga, Symbicort$326$14,10522 claims
AbbVieSynthroid$80$2,81445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →